Ubuvuzi bwa endoscope yubuvuzi (8) amashusho menshi (nka NBI / OCT)

Tekinoroji yerekana amashusho menshi, binyuze mumikoranire yumucyo wuburebure bwimyanya itandukanye hamwe nuduce, ibona amakuru yimbitse yibinyabuzima birenze endoskopi yumucyo wera, kandi byabaye urugero rwa zahabu mugupima kanseri hakiri kare no kubagwa neza. Ibikurikira bitanga isesengura rifatika ryubu buhanga bwo guhindura ibintu kuva murwego ndwi:

1. Amahame ya tekiniki nifatizo zifatika

Kugereranya uburyo bukoreshwa:

Guhuza Multimodal:

Sisitemu ihuriweho na NBI-OCT (nka Olympus EVIS X1): NBI igaragaza ahantu hakekwa → OCT isuzuma ubujyakuzimu

Fluorescence OCT (yakozwe na MIT): Fluorescence yanditseho ibibyimba → OCT isobanura imipaka yo kwanga

2.Ikoranabuhanga ryibanze no guhanga udushya

Iterambere ry'ikoranabuhanga rya NBI:

Ikoreshwa rya tekinoroji ya optique: Umuyoboro mugari wa filteri yumurongo <30nm (ipatanti ya Olympus)

Ikigereranyo cy’uburebure bubiri: 415nm (imashusho ya capillary) + 540nm (imitsi ya subucosal)

Ubwihindurize bwa sisitemu ya OCT:

Indangantego ya OCT: umuvuduko wo gusikana wiyongereye kuva kuri 20kHz ugera kuri 1.5MHz (nka Thorlabs TEL320)

Ubushakashatsi bwa Miniature: 1.8mm ya diametre izunguruka (ibereye ERCP)

AI yongereye isesengura:

Ibyiciro bya NBI VS (Icyiciro / Icyiciro cya Surface)

OCT imiyoboro ya glandular itandukanya algorithm (ubunyangamugayo> 93%)

3. Gukoresha ivuriro nagaciro ko gusuzuma

Ibimenyetso bya NBI:

Kanseri yo hambere ya Esophageal (IPCL yashyizwe mu byiciro): B1 ibyiyumvo byo gutahura imitsi bigera kuri 92.7%

Polyps y'amabara (NICE itondekanya): itandukaniro rya adenoma ryiyongereye kugera kuri 89%

Ibyiza bidasanzwe bya OCT:

Cholangiocarcinoma: Kumenyekanisha ibyangiritse kurwego rwurukuta rwumuyoboro <1mm

Esophagus ya Barrett: gupima uburebure bwa hyperplasia idasanzwe (uburebure bwa 10 μ m)

Ibyiza byubuvuzi:

Ikigo cy’igihugu cya kanseri y’Ubuyapani: NBI yongerera igipimo cya kanseri yo mu gifu hakiri kare kuva kuri 68% ikagera kuri 87%

Ishuri ry'ubuvuzi rya Harvard: OCT yayoboye ESD yo kubaga margin positivite igabanuka kugera kuri 2,3%

4. Guhagararira abakora nibipimo bya sisitemu

5. Ibibazo bya tekiniki nibisubizo

Imipaka ya NBI:

Umurongo wo kwiga urahanamye:

Igisubizo: AI yandika igihe nyacyo (nka ENDO-AID)

Kubura kwisuzumisha ibikomere byimbitse:

Kurwanya: EUS ihuriweho (Ultosound Endoscopique)

OCT icyuho:

Ibikoresho byerekana:

Iterambere: Holographic Optical Coherence Tomografiya (HOCT)

Urwego ruto rwo gufata amashusho:

Guhanga udushya: Panoramic OCT (nka scan izenguruka yakozwe na MIT)

6. Amajyambere agezweho yubushakashatsi

2024 Imipaka igabanuka:

Ikirangantego cyiza OCT: Caltech icamo imipaka (4 μ m → 1 μ m) ishingiye ku myigire yimbitse

Kugenda kwa molekulari: Kaminuza ya Heidelberg yamenye Raman NBI-OCT uburyo butatu bwo guhuza

Wambara NBI: Capsule NBI Yakozwe na Stanford (Kamere BME 2023)

Ibigeragezo bivura:

Ubushakashatsi buteganijwe: OCT guhanura kanseri yo mu gifu lymph node metastasis (AUC 0.91)

CONFOCAL-II: NBI + AI igabanya biopies idakenewe kuri 43%

7. Iterambere ry'ejo hazaza

Guhuza ikoranabuhanga:

Isomero ryubwenge bwibitabo: Buri pigiseli irimo 400-1000nm yuzuye ya spekure yamakuru

Akadomo ka Quantum: Utudomo twa CdSe / ZnS byongera itandukaniro ryihariye

Kwagura gusaba:

Kubaga kubaga: Igihe nyacyo OCT igenzura kubungabunga imitsi (kubaga kanseri ya prostate)

Isuzuma rya farumasi: NBI ingano ya mucosal angiogenez (Gukurikirana indwara ya Crohn)

guhanura isoko:

Mu 2026, isoko rya NBI ku isi rizagera ku $ 1.2B (CAGR 11.7%)

Igipimo cya OCT cyinjira mubice bya gallbladder na pancreas bizarenga 30%

Incamake n'ibitekerezo

Kwerekana amashusho menshi ni ugutwara endoskopi mugihe cya "optique biopsy":

NBI: Guhinduka 'Optical Staining' Standard yo gusuzuma Kanseri Yambere

OCT: Gutezimbere muri vivo pathology igikoresho

Intego nyamukuru: Kugera kumurongo wuzuye "digital pathology" kandi uhindure rwose paradigima yo gusuzuma tissue